D. I. Peregud, A. I. Korolkov, V. Y. Baronets, A. S. Lobacheva, M. L. Arkus, S. A. Igumnov, S. V. Pirozhkov, N. N. Terebilina
{"title":"酒精戒断综合征期间BDNF、miR-30a-5p和miR-122的含量","authors":"D. I. Peregud, A. I. Korolkov, V. Y. Baronets, A. S. Lobacheva, M. L. Arkus, S. A. Igumnov, S. V. Pirozhkov, N. N. Terebilina","doi":"10.1134/S1990750822040060","DOIUrl":null,"url":null,"abstract":"<p>Some brain-derived neurotrophic factor (BDNF)-targeted miRNAs such as miR-30a-5p may be associated with alcohol addiction; however, their relationship with alcohol withdrawal syndrome (AWS) is not described. We aimed to measure serum BDNF concentration and relative content of miR-30a-5p over the course of alcohol abstinence and compare results with the clinics of AWS. Apart from that, we studied the serum relative content of miR-122, a miRNA that does not target BDNF but is associated with alcohol use disorder. Serum BDNF concentration increases over the course of alcohol abstinence. In contrast, the relative content of miR-122, but not miR-30a-5p, decreased. Moreover, miR-122 (but not miR-30a-5p) negatively correlated with serum BDNF concentrations in the course of AWS. The relative content of miR-122 negatively correlated with depression and anxiety levels on day 8 of abstinence. According to multiple regression analysis, the severity of craving for alcohol and cognitive disturbances may be predictors of serum BDNF concentration on day 21 of abstinence, and vice versa. Thus, serum BDNF concentration and relative content of miR-122 are associated with some aspects of AWS clinical manifestations and may dynamically reflect AWS severity.</p>","PeriodicalId":485,"journal":{"name":"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry","volume":"16 4","pages":"353 - 363"},"PeriodicalIF":0.6000,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Contents of BDNF, miR-30a-5p AND miR-122 during Alcohol Withdrawal Syndrome\",\"authors\":\"D. I. Peregud, A. I. Korolkov, V. Y. Baronets, A. S. Lobacheva, M. L. Arkus, S. A. Igumnov, S. V. Pirozhkov, N. N. Terebilina\",\"doi\":\"10.1134/S1990750822040060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Some brain-derived neurotrophic factor (BDNF)-targeted miRNAs such as miR-30a-5p may be associated with alcohol addiction; however, their relationship with alcohol withdrawal syndrome (AWS) is not described. We aimed to measure serum BDNF concentration and relative content of miR-30a-5p over the course of alcohol abstinence and compare results with the clinics of AWS. Apart from that, we studied the serum relative content of miR-122, a miRNA that does not target BDNF but is associated with alcohol use disorder. Serum BDNF concentration increases over the course of alcohol abstinence. In contrast, the relative content of miR-122, but not miR-30a-5p, decreased. Moreover, miR-122 (but not miR-30a-5p) negatively correlated with serum BDNF concentrations in the course of AWS. The relative content of miR-122 negatively correlated with depression and anxiety levels on day 8 of abstinence. According to multiple regression analysis, the severity of craving for alcohol and cognitive disturbances may be predictors of serum BDNF concentration on day 21 of abstinence, and vice versa. Thus, serum BDNF concentration and relative content of miR-122 are associated with some aspects of AWS clinical manifestations and may dynamically reflect AWS severity.</p>\",\"PeriodicalId\":485,\"journal\":{\"name\":\"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry\",\"volume\":\"16 4\",\"pages\":\"353 - 363\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2022-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry\",\"FirstCategoryId\":\"2\",\"ListUrlMain\":\"https://link.springer.com/article/10.1134/S1990750822040060\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry","FirstCategoryId":"2","ListUrlMain":"https://link.springer.com/article/10.1134/S1990750822040060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Contents of BDNF, miR-30a-5p AND miR-122 during Alcohol Withdrawal Syndrome
Some brain-derived neurotrophic factor (BDNF)-targeted miRNAs such as miR-30a-5p may be associated with alcohol addiction; however, their relationship with alcohol withdrawal syndrome (AWS) is not described. We aimed to measure serum BDNF concentration and relative content of miR-30a-5p over the course of alcohol abstinence and compare results with the clinics of AWS. Apart from that, we studied the serum relative content of miR-122, a miRNA that does not target BDNF but is associated with alcohol use disorder. Serum BDNF concentration increases over the course of alcohol abstinence. In contrast, the relative content of miR-122, but not miR-30a-5p, decreased. Moreover, miR-122 (but not miR-30a-5p) negatively correlated with serum BDNF concentrations in the course of AWS. The relative content of miR-122 negatively correlated with depression and anxiety levels on day 8 of abstinence. According to multiple regression analysis, the severity of craving for alcohol and cognitive disturbances may be predictors of serum BDNF concentration on day 21 of abstinence, and vice versa. Thus, serum BDNF concentration and relative content of miR-122 are associated with some aspects of AWS clinical manifestations and may dynamically reflect AWS severity.
期刊介绍:
Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry covers all major aspects of biomedical chemistry and related areas, including proteomics and molecular biology of (patho)physiological processes, biochemistry, neurochemistry, immunochemistry and clinical chemistry, bioinformatics, gene therapy, drug design and delivery, biochemical pharmacology, introduction and advertisement of new (biochemical) methods into experimental and clinical medicine. The journal also publishes review articles. All issues of the journal usually contain solicited reviews.